Davit Baliashvili, Tsira Merabishvili, Irina Tskhomelidze, Maia Tsereteli, Lika Karichashvili, Nazi Chitadze, Paige A Armstrong, Maia Butsashvili
{"title":"Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia.","authors":"Davit Baliashvili, Tsira Merabishvili, Irina Tskhomelidze, Maia Tsereteli, Lika Karichashvili, Nazi Chitadze, Paige A Armstrong, Maia Butsashvili","doi":"10.1111/jvh.14022","DOIUrl":"https://doi.org/10.1111/jvh.14022","url":null,"abstract":"<p><p>Exposure to healthcare procedures might be a source of hepatitis C virus (HCV) transmission in Georgia, one of the few countries currently on track to eliminate hepatitis C. While there has been a history of iatrogenic transmission of HCV, the risk of HCV transmission related to endoscopic procedures has not been previously assessed in Georgia. The goal of this study was to assess HCV seroconversion among individuals undergoing endoscopic procedures to estimate the relative role and incidence of HCV infection attributable to endoscopic procedures. A prospective cohort study was conducted in four endoscopy units in two cities (Tbilisi and Kutaisi) of Georgia during April-September, 2021. Recruitment of study participants was conducted using convenience sampling, and every eligible patient was approached and invited to participate in the study. Study population included adults (age ≥ 18 years) who received an endoscopic procedure (gastroscopy, colonoscopy and bronchoscopy) in inpatient or outpatient unit at the study sites. HCV antibody (anti-HCV) testing was conducted using rapid diagnostic test (RDT) on the same day they underwent the endoscopic procedure. Patients with a non-reactive anti-HCV baseline test were retested after 6 months. Patients with reactive baseline tests were excluded from the study and linked to further testing and care. Participants with a reactive result on follow-up RDTs were retested using a lab-based anti-HCV and HCV ribonucleic acid (RNA) test. A total of 981 HCV antibody non-reactive participants were enrolled; 590 (64.8%) of them were reached and retested after 6 months. At retesting, two out of 590 (0.3%) individuals had a reactive anti-HCV result on RDT and both were negative on laboratory-based anti-HCV and HCV RNA tests. Based on the results of this study, endoscopic procedures were not shown to contribute to HCV transmission in Georgia.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of Knowledge, Attitudes and Practices for Hepatitis B Virus Infection Among Primary Healthcare Physicians in Georgia","authors":"Mamuka Zakalashvili, Sophia Surguladze, Davit Baliashvili, Jaba Zarkua, Tata Avalishvili, Elene Tsirdava, Mariam Tsodolishvili, David Metreveli, Natia Shavgulidze, Irina Tskhomelidze, Shaun Shadaker, Maia Tsereteli, Paige A. Armstrong, Senad Handanagic","doi":"10.1111/jvh.14011","DOIUrl":"10.1111/jvh.14011","url":null,"abstract":"<p>A nationwide serosurvey among adults in 2021 showed a 2.7% (95% confidence interval [CI]: 2.3%–3.4%) prevalence of hepatitis B. Our analysis evaluates knowledge, attitudes and practices (KAP) for hepatitis B virus (HBV) infection among primary healthcare physicians (PHPs) in Georgia. We randomly selected 550 PHPs from medical facilities in Georgia's six largest cities. Using bivariate ordinal regression, we assessed the association of socio-demographic factors with an ordinal knowledge score (low/middle/high). Multivariable logistic regression was performed to calculate adjusted odds ratios (aOR) and 95% CI to determine associations between HBV knowledge score and practices. Of 550 selected PHPs, 506 (92.0%) agreed to participate. Among them, 62.8% scored in the medium or high knowledge tertiles, 72.7% were confident in diagnosing HBV infection, 37.3% were confident in managing patients with hepatitis B; 47.4% reported being screened for and 26.2% reported being vaccinated against HBV infection. Compared to those with low knowledge scores, PHPs with a high score were less likely to recommend activities not supported by evidence, such as: the use of ‘hepatoprotective’ medications (aOR 0.43, 95% CI 0.25–0.73), caesarean sections (aOR 0.47, 95% CI 0.27–0.82) and withholding breastfeeding (aOR 0.57, 95% CI 0.34–0.96) to prevent HBV transmission. The majority of PHPs were confident in diagnosing HBV infection, but only one in three were confident in managing patients with hepatitis B. PHPs with higher HBV knowledge were less likely to provide inaccurate instructions to their patients. These findings will help to develop awareness and education campaigns supporting HBV elimination in Georgia.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"31 12","pages":"880-889"},"PeriodicalIF":2.5,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adeel A Butt, Peng Yan, Rahel Iwnetu, Amyn A Malik, Obaid S Shaikh, Jacqueline G O'Leary, Roger Bedimo
{"title":"Hepatitis Delta Coinfection Rates and All-Cause Mortality Among Hepatitis B-Infected Veterans in the USA.","authors":"Adeel A Butt, Peng Yan, Rahel Iwnetu, Amyn A Malik, Obaid S Shaikh, Jacqueline G O'Leary, Roger Bedimo","doi":"10.1111/jvh.14021","DOIUrl":"https://doi.org/10.1111/jvh.14021","url":null,"abstract":"<p><p>Screening for hepatitis D virus (HDV) is recommended for all individuals with hepatitis B virus (HBV) infection. Coinfected individuals experience more severe liver-related outcomes. We determined the HDV testing and coinfection rates and all-cause mortality among those infected with HBV. We used the US Department of Veterans Affairs (VA) healthcare system's national databases to identify individuals with HBV infection. We determined the proportion of individuals referred to gastroenterologists/hepatologists, or infectious diseases providers, and the proportion screened and tested positive for HDV. We calculated the HBV treatment rates, defined as ≥ 3 months of continuous prescription with an approved drug. Finally, we calculated all-cause mortality stratified by HDV coinfection and HBV treatment status. Among 44,951 individuals with at least one positive HBsAg, HBeAg or HBV DNA test, 5964 (13.3%) were screened for HDV (180 [3.0%] tested positive), and 28,291 (62.9%) were referred to gastroenterology/hepatology or infectious diseases. Treatment for HBV was prescribed for 73 (40.5%) of HDV-coinfected and 2425 (41.9%) HDV-uninfected individuals. All-cause mortality rate per 100 person-years was lower among those without HDV coinfection (2.98 for untreated HBV, 2.53 for treated HBV; p < 0.001) compared with those with HDV coinfection (5.14 for untreated HBV, 3.0 for treated HBV; p = 0.02). Kaplan-Meier curves demonstrated a significantly higher mortality among HDV-coinfected individuals who were not treated for HBV (log-rank p < 0.0001). Screening rates for HDV among HBV-infected individuals are suboptimal. While HDV coinfection is associated with higher all-cause mortality, HBV treatment may confer a survival benefit.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuxin Chen, Xiujun Zhang, Xiaomin Yan, Li Wang, Mingzhe Ning, Bei Jia, Renlin Yao, Fan Zhang, Juan Xia, Zhaoping Zhang, Yongyang Zhang, Yali Xiong, Weihua Wu, Sufang Lu, Han Shen, Rui Huang, Longgen Liu, Chao Wu
{"title":"A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China.","authors":"Yuxin Chen, Xiujun Zhang, Xiaomin Yan, Li Wang, Mingzhe Ning, Bei Jia, Renlin Yao, Fan Zhang, Juan Xia, Zhaoping Zhang, Yongyang Zhang, Yali Xiong, Weihua Wu, Sufang Lu, Han Shen, Rui Huang, Longgen Liu, Chao Wu","doi":"10.1111/jvh.14020","DOIUrl":"https://doi.org/10.1111/jvh.14020","url":null,"abstract":"<p><p>Hepatitis C virus (HCV) infection is a major public health burden in China, affecting more than 10 million individuals. We aimed to evaluate the effectiveness of a hospital-based intervention programme for HCV Surveillance with linkage to care (HEAL) in a prospective cohort. The HEAL programme was carried out targeting inpatients from non-infectious departments of two tertiary hospitals in Jiangsu, China. It consisted of an educational campaign to raise awareness of physicians from non-IDs to promote HCV surveillance, a patient-navigator-centred clinical algorithm responsible for the efficient follow-up of patients with positive HCV antibody, including comprehensive testing, diagnosis and treatment. We characterised the rate of linkage to HCV diagnosis, care and treatment during the pre-intervention period (from 1 July 2016 and June 30, 2018) and after the intervention (from March 2019 to May 2021). During the pre-intervention period, 89,303 (45.3%) out of 196,780 non-ID inpatients were screened for anti-HCV, and 631 patients were tested positive. One hundred and fifty-six (24.7%) patients was followed up for HCV RNA confirmatory testing, and 58 (37.1%) of patients further were diagnosed with chronic HCV infection (CHC). Only 18 (31.3%) of the diagnosed patients with CHC were linked to hepatitis C clinics for treatment, 10 (55.6%) patients received antiviral regimen. Among them, two (11.1%) received DAA treatment, while eight (44.4%) adopted peginterferon/ribavirin regimen. During the intervention period, 232,275 patients were hospitalised in non-infectious department and 151,203 (65.1%) were screened for anti-HCV. Of these, 960 patients tested positive for HCV antibodies, resulting in a prevalence of anti-HCV positivity of 0.63%. Six hundred and seventy (69.8%) patients were enrolled, and 100% were followed up for HCV RNA confirmatory testing. Two hundred and ninety-one (43.4%) individuals with active HCV were identified. Two hundred and thirty-eight (81.8%) of HCV-infected individuals were linked to HCV care, and 157 (65.9%) were linked to treatment. Compared to the pre-intervention period, there was a 2.61-fold increase in the percentage of patients linked to care and a 5.94-fold increase in the proportion of patients who started DAAs therapy. This HEAL programme achieved enhanced HCV Surveillance with linkage to care, which has been demonstrated as an effective strategy in the hospital setting to improve the hepatitis C care continuum by identifying inpatients unaware of their HCV status and facilitating their access to HCV treatment.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognosis of Acute HEV Infection in Patients With Liver Cirrhosis: A Retrospective Study of 628 Chinese Patients.","authors":"Wen An, Mengqi Li, Jing Luo, Zhe Yu, Hongshan Wei","doi":"10.1111/jvh.14018","DOIUrl":"https://doi.org/10.1111/jvh.14018","url":null,"abstract":"<p><p>Acute hepatitis E virus infection is a serious global health problem, which a significant cause of morbidity and mortality. The aim of the present study was to characterise the clinical features and therapeutic response of patients with acute HEV infection and identify risk factors for poor prognosis. In a retrospective study from 01 January 2014 to 01 Januray 2022, we collected baseline data from all patients eligible for acute hepatitis E virus (HEV) infection and followed up with all patients via interviews and medical records. We explored the clinical feature of Chinese patients with acute HEV infection. The follow-up data of patients were used to identify risk factors for poor prognosis. In total, 628 acute hepatitis E (AHE) patients fulfilled the inclusion criteria and did not meet the exclusion criteria. Among them, 452 were males and 176 were females (M:F = 2.57:1). The median age at diagnosis was 57.0 years (interquartile range: 46-64 years). The median baseline serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) were elevated in this cohort (642.3 U/L, 216.2 U/L, 104.1 μmol/L, respectively). The median hospitalisation duration was 16 days. Compared with patients without other liver diseases, patients with liver cirrhosis show lower baseline ALT and AST level, poorer coagulation indices and higher MELD scores. According to multivariate analysis, liver cirrhosis, high MELD score, low albumin concentration was found to be independent predictors of poor prognosis in patients with AHE. Our study used a lager sample size to validate that some demographic and serological features were quite different between patients with/without CLDs. Liver cirrhosis was a significant independent predictor of poor prognosis in acute HEV hepatitis.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Naw April Phaw, Danielle Rayner, Amy Johnson, Craig Thompson, Stuart McPherson
{"title":"Harm Minimisation and Other Preventative Measures Must Improve to Reduce Transmission of Hepatitis C in Prisons.","authors":"Naw April Phaw, Danielle Rayner, Amy Johnson, Craig Thompson, Stuart McPherson","doi":"10.1111/jvh.14017","DOIUrl":"https://doi.org/10.1111/jvh.14017","url":null,"abstract":"","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Multiple Low-Level Viraemia Suggest Hindered Liver Fibrosis Regression in Chronic Hepatitis B Patients During Antiviral Therapy","authors":"Zhengzhao Lu, Ya-Meng Sun, Shuyan Chen, Tongtong Meng, Bingqiong Wang, Jialing Zhou, Xiaoning Wu, Xinyan Zhao, Xiaojuan Ou, Yuan-Yuan Kong, Jidong Jia, Xinyu Zhao, Hong You","doi":"10.1111/jvh.14012","DOIUrl":"10.1111/jvh.14012","url":null,"abstract":"<div>\u0000 \u0000 <p>Low-level viraemia (LLV) occurs in chronic hepatitis B (CHB) patients despite antiviral treatment, which may cause failed histological regression. Our study aimed to investigate the impact of different LLV types on fibrosis regression. The prospective study enrolled CHB patients with paired liver biopsies before and after 260 weeks of entecavir treatment. Fibrosis regression was defined by the Ishak score or P-I-R system. Patients were grouped as the SVR (HBV DNA < 20 IU/mL persistently) or LLV (HBV DNA between 20 and 2000 IU/mL), which were further grouped as very low-level viraemia (VLLV, HBV DNA < 50 IU/mL), occasionally LLV (OLLV, HBV DNA ≥ 50 IU/mL only once) and multiple LLV (MLLV, HBV DNA ≥ 50 IU/mL more than once). Logistic regression models were used to calculate the adjusted odds ratios (aORs) and 95% confidence intervals (CIs). The analysis included 111 CHB patients. In the SVR group (<i>n</i> = 54), 39 (72.2%) patients had fibrosis regression, which was higher than the LLV (56.1%, <i>p</i> = 0.080). The fibrosis regression rates for VLLV (30 patients), OLLV (17 patients) and MLLV (10 patients) were 70.0%, 52.9% and 30.0%, respectively. Compared with SVR, VLLV (aOR = 0.78; 95% CI: 0.28–2.21; <i>p =</i> 0.644) was not associated with fibrosis regression, but patients with non-VLLV (aOR = 0.27; 95% CI: 0.09–0.85; <i>p =</i> 0.025), especially with MLLV (aOR = 0.19; 95% CI: 0.04–0.97; <i>p =</i> 0.046) is significantly associated with hindered fibrosis regression. Our study suggests that patients with detectable serum HBV DNA levels higher than 50 IU/mL need to be monitored carefully, especially in those with more than once.</p>\u0000 <p><b>Trial Registration:</b> ClinicalTrials.gov identifiers NCT01938781 and NCT01938820</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"31 12","pages":"898-902"},"PeriodicalIF":2.5,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply: Regarding the Predictive Role of CXCL16 in Liver Inflammation in Chronic Hepatitis B Patients","authors":"Yawen Wan, Shengxia Yin, Chao Wu","doi":"10.1111/jvh.13996","DOIUrl":"10.1111/jvh.13996","url":null,"abstract":"<p>We have received your letter and thank you very much for your hard work. We are very pleased that the reader has carefully read the article, and we also greatly appreciate the valuable feedback provided by Zhang. I provide the following response to Zhang's question.</p><p>Firstly, we conducted an univariate logistic regression analysis to preliminarily identify the associated factors with severe liver inflammation. Considering the close relationship between these parameters and liver inflammation in univariate analysis, factors with <i>p</i> < 0.05 were adjusted for further multivariate analysis. However, we totally agree with Zhang's comments that a larger sample size is more appropriate for this analysis, but we encountered great difficulties in collecting serum samples. Due to the fact that liver puncture is an invasive examination and our inclusion criteria are strict, therefore it is difficult to obtain samples that meet the standards. I hope to gain the reader's understanding regarding this matter.</p><p>Secondly, how I adjust which factors to enter into multivariate logistic regression analysis and choose which factors to build the model is a key question. I would like to discuss my viewpoint and hope to receive Zhang's support. (1) This factor must have statistical significance in univariate logistic regression analysis. (2) This factor is of great significance in practical clinical work, such as alanine aminotransferase (ALT), platelet (PLT) and albumin (ALB), which can evaluate the progression of liver diseases from different aspects. (3) We have considered the correlation between factors. If there is a strong correlation between factors, it may affect the stability of the model. (4) We have done a lot of statistical work, arranging and combining these factors separately for statistical analysis. We compared the final results and came to a conclusion. We found that CXCL16, ALT, PLT and ALB were statistically significant in the multivariate logistic regression analysis, and the predictive model was the most representative. Due to the large and complex statistical information, we did not present all statistical results in the article. (5) Our mouse experiments confirmed a strong correlation between CXCL16 and liver inflammation. I apologize for the confusion caused to Zhang and other readers.</p><p>Thirdly, Zhang raised the issue of the impact of antiviral drugs on patients with chronic hepatitis B, which is indeed worth considering. However, we have excluded patients who underwent antiviral therapy at enrollment, as clearly indicated in exclusion criteria.</p><p>In future research, we will gradually expand the sample size and consider more factors that affect the outcomes of patients with chronic hepatitis B. We look forward to collaborating with Zhang and other readers. We sincerely thank you again for your valuable letter.</p><p>Sincerely yours,</p><p>Chao Wu, MD, PhD.</p><p>All authors reviewed this manuscript and agreed to subm","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"31 12","pages":"905-906"},"PeriodicalIF":2.5,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Osman Cagin Buldukoglu, Serkan Ocal, Ayhan Hilmi Cekin
{"title":"Disparities in the Detection, Diagnosing and Treatment of Hepatitis B Among Females","authors":"Osman Cagin Buldukoglu, Serkan Ocal, Ayhan Hilmi Cekin","doi":"10.1111/jvh.14013","DOIUrl":"10.1111/jvh.14013","url":null,"abstract":"","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"31 12","pages":"903-904"},"PeriodicalIF":2.5,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Helen L. Zhang, Hayley Nemeth, E. Wilbur Woodhouse, Clemontina A. Davenport, Cliburn Chan, Nwora Lance Okeke, Susanna Naggie
{"title":"Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure","authors":"Helen L. Zhang, Hayley Nemeth, E. Wilbur Woodhouse, Clemontina A. Davenport, Cliburn Chan, Nwora Lance Okeke, Susanna Naggie","doi":"10.1111/jvh.14009","DOIUrl":"10.1111/jvh.14009","url":null,"abstract":"<div>\u0000 \u0000 <p>A subset of patients with chronic hepatitis C virus (HCV) infection demonstrate liver enzyme elevation (LEE) after achieving sustained virologic response (SVR). Risk factors for LEE are not well characterised. We conducted a single-centre retrospective cohort study of adults with HCV infection in the Duke University Health System who received direct-acting antiviral therapy and achieved SVR. We performed multivariable logistic regression to assess the relationship between potential risk factors and LEE. We used generalised linear mixed-effects models to explore longitudinal relationships between HIV and LEE. Among 1356 patients, 556 (41.0%) had LEE after achieving SVR. Higher pretreatment alanine aminotransferase (ALT) (adjusted odds ratio [aOR] 1.08 per 10 IU/L increase; 95% confidence interval [CI] 1.05–1.11) and pretreatment cirrhosis (aOR 2.26, 95% CI 1.60–3.21) were associated with higher odds of LEE; male sex was associated with lower odds of LEE (aOR 0.28, 95% CI 0.21–0.38). There was insufficient evidence of an association between HIV and LEE (aOR 0.83, 95% CI 0.47–1.44). Pretreatment ALT, cirrhosis and female sex predicted LEE in this cohort of patients with HCV infection who achieved SVR. These findings can help to identify patients at greatest risk of post-SVR liver injury.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"31 12","pages":"866-872"},"PeriodicalIF":2.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}